Jobs
-
Gossamer Bio announced that it has reacquired the ex-US rights to its seralutinib dry powder inhaler for the treatment of pulmonary hypertension from Chiesi, which acquired the rights to the seralutinib DPI in 2024. According to… Read more . . .
-
US-based biopharm Revagenix announced that it has initiated a Phase 1 trial of Rev-56, which it describes as an “inhaled, anti-pseudomonal therapy for non-cystic fibrosis bronchiectasis (NCFB).” The first part of the study will evaluate… Read more . . .
-
According to Cipla, the FDA has approved the company’s ANDA for 100/50 mcg, 250/50 mcg, and 500/50 mcg strengths of its generic version of Advair Diskus fluticasone propionate / salmeterol DPI for the treatment of… Read more . . .
-
According to Cessatech, the EMA’s Committee for Medicinal Products for Human Use has adopted a negative opinion regarding Proveca’s pediatric-use marketing authorization (PUMA) of KemSu (CT001) sufentanil / ketamine nasal spray for the treatment of… Read more . . .
-
According to Aptar Pharma, parent company of OINDP-focused CRO Nanopharm, the UK Medicines and Healthcare Products Regulatory Agency has completed an inspection of Nanopharm’s facility in Cwmbran, Wales and has certified the location as GMP compliant.… Read more . . .
-
According to AstraZeneca, the Australian Therapeutic Goods Administration has approved a reformulated Breztri (Trixeo) Aerosphere budesonide / glycopyrronium / formoterol fumarate MDI with Solstice‘s Solstice Air HFO-1234ze as the propellant. Breztri is approved in Australia for the treatment of… Read more . . .
-
Both Chiesi and the UK’s Medicines and Healthcare products Regulatory Agency have announced the MHRA’s approval of a reformulated Clenil Modulite beclometasone MDI for the treatment of asthma, marking the first approval of an MDI using Orbia‘s HFA 152a as… Read more . . .
-
According to Glenmark, the FDA has approved the company’s sNDA to extend the use of Ryaltris olopatadine / mometasone nasal spray for the treatment of seasonal allergic rhinitis to patients aged 6 -12. Ryaltris was… Read more . . .
-
Eli Lilly and Company has agreed to pay approximately $2.8 billion up front and up to an additional $1 billion in milestone payments for pyschedelics developer AtaiBeckley, the companies said. AtaiBeckley’s lead candidate is BPL-003… Read more . . .
-
Dutch CDMO Basic Pharma announced that German investment firm SHS Capital has acquired a majority stake in the company, with the investment expected to support additional manufacturing capacity. The announcement highlights Basic Pharma’s development and… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden